Search Results

Concord Medical Services Holdings Limited today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 (the “Annual Report”) with the U.S. Securities and Exchange Commission.

Concord Medical Services Holdings Limited announced that it has received a letter from the New York Stock Exchange dated February 12, 2024, notifying the Company that it is below compliance standards due to the trading price of the Company’s American depositary shares and that the applicable cure period for the Company to regain compliance expires on August 12, 2024.

Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2023.

Concord Medical Services Holdings Limited announced the successful holding of the Second Annual Academic Meeting jointly by Shanghai Concord Cancer Center and The University of Texas MD Anderson Cancer Center on November 11 and November 12, 2022.

Concord Medical Services Holdings Limited today announced that it will hold its 2022 annual general meeting of shareholders (the “Meeting”) on December 30, 2022, at 10:00 a.m. (Beijing Time).